



Proteomics International

LABORATORIES LTD

Media/ASX Release

27 March 2017

ASX code: PIQ

Frost & Sullivan independent industry report identifies PromarkerD as the world leading test for diabetic kidney disease

Proteomics International Laboratories Ltd (ASX: PIQ) (PILL) is the leader in predictive diagnostics for diabetic kidney disease according to a Frost & Sullivan independent report released this month. PILL managing director Dr Richard Lipscombe will be showcasing PromarkerD at the China-Australia Biotech Investment forum in Shanghai today.

Dr Lipscombe said the new report, titled *Biomarkers Enabling Diabetes and Obesity Management*, identifies PromarkerD as the world leader. The independent report says novel biomarker research “is likely to transform the future of obesity and diabetes management”.

The respected research house goes on to highlight PILL's novel test for diabetic kidney disease, called PromarkerD, noting its “high adoption potential” ([link](#) to report).

Frost & Sullivan states that novel tools like PromarkerD can allow “enhanced management of obesity, diabetes and related complications in the near future”.

There is currently no available test for predicting the onset of diabetic kidney disease and Frost & Sullivan suggest PILL is one of only two companies worldwide developing such a test. Results have shown PromarkerD can correctly predict 95% of previously kidney disease-free diabetic patients who go on to develop chronic kidney disease.

This follows news that the PromarkerD technology has been validated by the peer-reviewed scientific journal *EuPA Open Proteomics*, the official journal of the European Proteomics Association (EuPA).

Kidney disease is one of the major complications of diabetes and affects approximately one-third of all adult diabetics. Keeping people alive on dialysis costs more than \$100,000 per person per year.

Globally the diabetes epidemic cost health systems \$673 billion dollars in 2015.

Dr Lipscombe said early detection is key to saving lives and money. “PromarkerD means we can accurately predict if someone will get the disease in the next four years so they can take lifestyle and medication action immediately to cut their risks,” he said.

“If we can stem this health crisis tsunami by identifying and treating people before they are symptomatic we are saving lives, as well as billions of dollars in health costs.”

Publication details

‘*Biomarkers Enabling Diabetes and Obesity Management*’ published by Frost & Sullivan, March 2, 2017.

Click [here](#) for the report.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

'Comprehensive Mass Spectrometry Based Biomarker Discovery And Validation Platform As Applied To Diabetic Kidney Disease' published in *EuPA Open Proteomics*, the official journal of the European Proteomics Association, March 1, 2017. Click [here](#) for the research paper.

Multimedia

Presentation: An audio summary of the research paper. Click [here](#).

Video: The power of the Promarker platform for personalised medicine. Click [here](#).

PromarkerD - a predictive diagnostic test for diabetic kidney disease

The EuPA journal article followed evaluation by independent scientific experts and serves to verify the process used to develop and test PILL's PromarkerD protein 'fingerprint' that measures kidney disease in patients with diabetes. This novel test can both diagnose and predict disease.

In diabetic patients already suffering from chronic kidney disease PromarkerD could diagnose the presence of disease that was missed by the current gold standard tests (known as the ACR and eGFR tests).

Critically, PromarkerD can also predict the onset of disease before clinical symptoms appear. In an extension of the published work 576 patients were followed in a four-year longitudinal clinical study. PromarkerD correctly predicted 95% of the previously kidney disease-free diabetic patients who went on to develop chronic kidney disease.

About the Promarker Platform

PILL's diagnostic research is made possible by the company's proprietary biomarker discovery platform termed Promarker, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing.

The technology is so versatile it can be used to identify fingerprints from any biological source. The Promarker platform is also being applied to the asbestos-related cancer mesothelioma, the gastro-causing parasite *Giardia* (in partnership with a US veterinary company) and endometriosis, a condition that affects one in ten women in their reproductive years.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

Greg Wood [Corporate Advisor]
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

PILL (ASX: PIQ) is a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

of choice for the pharmaceutical industry because of their intimate role in biological systems. Thus proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas, each massive growth markets:

1. Diagnostics: Biomarkers of disease and personalised medicine - focus on diabetic kidney disease. By 2020 the biomarkers market is estimated to double in size to \$45.6 billion, and the personalised medicine market is forecast to be worth over \$149 billion.

2. Analytical services: Specialist contract research fee-for-service model – focus on biosimilars QC. The global biosimilars market is expected to reach \$6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.

3. Drug discovery: Therapeutic peptide drug discovery - focus on painkillers and antibiotics. The global peptide therapeutics market is currently estimated to be worth \$18 billion and is

e
x
p
e
c
t
e
d

t
o

i
n
c
r
e
a
s
e

b
y

o
v
e
r

1
0
%

p
e
r

y
e
a
r

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com